The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in ...

“It is likely that more and more, these newer agents are going to play earlier and more central roles in the early treatment of BCG-unresponsive disease," says Shreyas S. Joshi, MD, MPH. He explained, ...

A panelist discusses how the findings in the docetaxel-naive population show distinct differences in treatment efficacy, with potentially greater benefits observed for certain androgen receptor ...

A panelist discusses how these comparative results could influence clinical decision-making by suggesting potentially different magnitudes of benefit between enzalutamide and darolutamide depending on ...

In a recent interview with Urology Times®, endourologist Perry Xu, MD, was asked about how he goes about shared decision-making in his practice. “Coupled with all of these innovations, there are also ...

The Glean Urodynamics System received FDA clearance, offering wireless, catheter-free monitoring for lower urinary tract dysfunction, improving patient comfort and data accuracy. The SureForm 45 ...

A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction. Welcome back to Pearls & Perspectives! In this episode of ...

Kevin C. Zorn, MD, FRCSC, FACS, recaps the AUA 2025 session, “State-of-the-Art Lecture: Preservation of Ejaculatory Function with BPH Treatments." Preservation of ejaculatory function is a top ...

Welcome back to Pearls & Perspectives, with Amy Pearlman, MD! In this 2-part episode of Pearls and Perspectives from the American Urological Association's (AUA) 2025 Annual Meeting in Las Vegas, NV, ...

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical ...

Video content above is prompted by the following: Aqua Ablation Therapy Benefits Efficacy: Aqua ablation demonstrates noninferior, equal, or superior results compared with TURP (gold standard).

TAR-200 monotherapy achieved a 6-month DFS of 85.3% and a 9-month DFS of 81.1% in BCG-unresponsive high-risk NMIBC patients. The trial reported high PFS (95.6%) and OS (98.0%) rates at 9 months, with ...